Pasithea wins FDA clearance for Phase 2 trial of PAS-004 in cutaneous neurofibromas
KTTA•Pasithea Therapeutics received FDA clearance to begin a randomized, placebo-controlled Phase 2 trial of PAS-004 for NF1-associated cutaneous neurofibromas.
1. Trial clearance
The trial will study PAS-004 for NF1-associated cutaneous neurofibromas, a condition affecting over 95% of people with NF1. There are no FDA-approved systemic therapies for the condition.
